Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

lammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "plan"; "should"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. No forward-looking statement can be guaranteed. Risks and uncertainties include risks associated with whether the development of the product described in this press release will be successful or whether the data from the registrational program described in this press release will support the filing of a Biological License Application (BLA) with the U.S. Food and Drug Administration (FDA, or if a BLA is filed with the
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Repeated exposure to broad-spectrum antibiotics in the first two ... say researchers from The Children,s Hospital of ... data from electronic health records from the extensive CHOP ... children with four or more exposures to broad spectrum ... at risk for obesity. The study, published online September ...
(Date:9/29/2014)... Pharmacists have an important role in ... good clinical trials practices. The Hematology/Oncology Pharmacy Association ... Practice Standards, the first of its kind that ... pharmacists and institutions that conduct clinical trials. The ... the critical role of the pharmacist in the ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 ... Summary GlobalData,s new report, "EU5 ... market data on the EU5 Capsule Endoscopy Systems market. ... volume (in units) and average prices (in US dollars) ... Recorders and Capsule Endoscopy Workstations. The report ...
Breaking Medicine Technology:Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3
... and Company (NYSE: LLY ) announced the ... Committee voted today to recommend non-approval of liprotamase, a ... review for the treatment of exocrine pancreatic insufficiency (EPI). ... questions about the degree of efficacy of liprotamase and ...
... gloStream, maker of gloEMR and gloPM – the only ... software with Microsoft Office built right in – today announced ... the gloEMR product line. Like its predecessor versions, gloEMR 6.0 ... platform, SQL Server and Microsoft Office so users have access ...
Cached Medicine Technology:Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency 2gloStream Announces Release of Microsoft-Based, Meaningful Use Certified gloEMR 6.0 2gloStream Announces Release of Microsoft-Based, Meaningful Use Certified gloEMR 6.0 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 TrailMyx.com ... its October Flavor of the Month: raw pumpkin seeds. ... seed of squash”)—are rich in protein, and valued by ... and multiple types of vitamin E. They are prized ... function and proper bowel function. , Of course, pumpkin ...
(Date:9/30/2014)... Pivotal 5, LLC, a proven leader in ... – The Healthy Way of Life CompanySM (NYSE: LTM) ... Training . KettleWorX Group Training is a three-dimensional training ... of all fitness levels a means to enter into ... rollout to Life Time Athletic destinations will be KettleWorX’s ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... 30, 2014 Visiting Nurse Association (VNA) ... pleased to announce that Steven Landers, MD, MPH, president ... “40 Under 40” award on Monday evening. The ... young businessmen and women who have been making headlines ... business growth, professional excellence and to the community. , ...
(Date:9/30/2014)... September 30, 2014 During this ... natural approaches to health including achieving hormonal balance, ... deficiencies and detoxification. , The ... , Date: October 6-9, 2014, Location: Online Event, ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven ...
Breaking Medicine News(10 mins):Health News:TrailMyx.com Features October Flavor of the Month 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2
... , CHERRY HILL, N.J., Aug. 25 Nuvilex, ... a shareholder newsletter on September 1, 2009. Additionally, regional shareholder meetings ... on September 17th, and Los Angeles on September 18th. Regional shareholder ... 7, 2009. , , "We are very aware ...
... , DES MOINES, Iowa, Aug. 25 The Graham ... Medical Plaza II, a three-story, 70,000 square-foot medical office building serving ... building located on the campus of Carondelet St. Mary,s Hospital, a ... The offices currently include the Carondelet Medical Group, a large family ...
... WILMINGTON, Del., Aug. 25 While many pharmaceutical ... and Mitigation Strategy (REMS) programs for many new and old ... program evaluations beginning just 1-1/2 years after each REMS is ... has been issued by risk management expert Jeffrey Fetterman, CEO ...
... Nottingham and Health Protection Agency East Midlands are carrying out ... as part of the government,s response to the pandemic. ... contagious for and advise on a ,safe distance, from the ... Nguyen Van Tam of the University of Nottingham,s School of ...
... TIPP CITY, Ohio, Aug. 25 One month ago, ... began his quest to bicycle through all 48 states in the continental U.S. ... hometown of Tipp City, Ohio, Nagle now has passed well beyond the halfway ... , , In addition to eyeing a Guinness World ...
... WASHINGTON, Aug. ... the United States $4.5 million to resolve allegations that it violated the ... , This ... financial relationships with five physicians that violated the Stark Law. The ...
Cached Medicine News:Health News:Nuvilex to Issue Positive Shareholder Newsletter 2Health News:Nuvilex to Issue Positive Shareholder Newsletter 3Health News:Nuvilex to Issue Positive Shareholder Newsletter 4Health News:Nuvilex to Issue Positive Shareholder Newsletter 5Health News:Nottingham scientists commissioned for urgent swine flu research 2Health News:College Student's '48 States in 48 Days' Bike Ride Moves Well Beyond the Halfway Point 2Health News:Covenant Medical Center to Pay U.S. $4.5 Million to Resolve False Claims Act Allegations 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: